NASDAQ$MRVI
Maravai LifeSciences Holdings Inc. · Q3 2024 earnings
Q3 2024 earnings · · Investor relations
Briefing
Reported third quarter results with revenue of $65.2 million and announced agreement to acquire the DNA and RNA business of Officinae Bio.
Maravai LifeSciences reported a 2.5% decrease in revenue for the third quarter, totaling $65.2 million. The company experienced a net loss of $(176.0) million, which included a goodwill impairment of $154.2 million. They updated their full-year revenue guidance for 2024 to a range of $255.0 million to $265.0 million.
- Quarterly revenue reached $65.2 million.
- Net loss was $(176.0) million, including a goodwill impairment of $154.2 million.
- Adjusted EBITDA was $12.7 million.
- Full year 2024 revenue guidance updated to $255.0 million to $265.0 million.
Headline financials
Revenue & EPS history
Maravai · Revenue · Quarterly
$63M
Revenue by segment
Maravai · $66.9M total across 2 segments · Q3 2023
- TriLink$51.2M-70.7%76.6%
- Cygnus$15.6M-4.5%23.4%
Forward guidance
Revenue expectations for 2024 are now expected to be in the range of $255.0 million to $265.0 million. Adjusted EBITDA (non-GAAP) margins are now expected to be in the range of 16% to 18%.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2024
-0.2%
Avg return
Earnings day
+2.1%
Avg return
5 days after
+1.1%
Avg return
30 days after
42%
10 / 24 earnings
Positive
+58.9%
Q4 2023
Best reaction
-36.7%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +23.4% | +10.9% | +27.5% | |
| Q4 2025 | +9.9% | +13.2% | -12.3% | |
| Q3 2025 | -0.7% | +12.5% | +28.0% | |
| Q1 2025 | -2.4% | -0.9% | +6.6% | |
| Q4 2024 | -6.4% | -13.2% | -31.4% | |
| Q3 2024 | -36.7% | -29.0% | -37.1% | |
| Q2 2024 | -6.7% | -4.3% | -0.4% | |
| Q1 2024 | +10.0% | +17.5% | -3.9% | |
| Q4 2023 | +58.9% | +57.0% | +66.5% | |
| Q3 2023 | -31.3% | -25.0% | -24.3% | |
| Q2 2023 | -3.5% | -10.1% | -5.7% | |
| Q1 2023 | -16.4% | +2.5% | -3.3% | |
| Q4 2022 | +6.9% | +3.2% | -2.4% | |
| Q3 2022 | -11.7% | -13.8% | -15.3% | |
| Q2 2022 | +2.2% | -3.5% | -20.7% | |
| Q1 2022 | +6.1% | -2.9% | +6.7% | |
| Q4 2019 | +1.4% | +1.1% | -9.7% | |
| Q4 2021 | -1.6% | +14.8% | +7.0% | |
| Q3 2020 | -1.7% | -0.4% | +6.3% | |
| Q3 2021 | +1.6% | +3.1% | +10.1% | |
| Q2 2021 | -5.7% | +8.8% | +0.6% | |
| Q1 2020 | +4.0% | +8.6% | +26.5% | |
| Q1 2021 | -4.8% | +2.1% | +13.1% | |
| Q4 2020 | -0.4% | -2.4% | -6.3% | |
| Q2 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro